3. Jabbour E, Hochhaus A, le Coutre P, et al. 2008; Minimal cross- intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP). J Clin Oncol (ASCO Annual Meeting Abstracts). 26(Suppl):7063. DOI:
10.1200/jco.2008.26.15_suppl.7063.
Article
4. Saglio G, Kim DW, Issaragrisil S, et al. 2010; Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 362:2251–9. DOI:
10.1056/NEJMoa0912614. PMID:
20525993.
Article
5. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. 2013; Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 27:107–12. DOI:
10.1038/leu.2012.181. PMID:
22763385.
Article
6. Novartis. 2010. Highlights of prescribing information: Tasigna (nilotinib) [package insert]. Novartis Pharma Stein;Stein, Switzerland: DOI:
10.1038/leu.2012.181.
7. le Coutre PD, Giles FJ, Hochhaus A, et al. 2012; Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 26:1189–94. DOI:
10.1038/leu.2011.323. PMID:
22076466.
Article
8. Baccarani M, Cortes J, Pane F, et al. 2009; Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 27:6041–51. DOI:
10.1200/JCO.2009.25.0779. PMID:
19884523. PMCID:
PMC4979100.
Article
10. Shin J, Koh Y, Yoon SH, et al. 2018; A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea. Cancer Med. 7:1814–23. DOI:
10.1002/cam4.1450. PMID:
29577674. PMCID:
PMC5943463.
Article
11. Hochhaus A, Saglio G, Hughes TP, et al. 2016; Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 30:1044–54. DOI:
10.1038/leu.2016.5. PMID:
26837842. PMCID:
PMC4858585.
Article
12. Baccarani M, Deininger MW, Rosti G, et al. 2013; European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 122:872–84. DOI:
10.1182/blood-2013-05-501569. PMID:
23803709. PMCID:
PMC4915804.
13. Kim DY, Lee JO, Kim KH, et al. 2015; Korean guidelines for treating chronic myelogenous leukemia - The Korean Society of Hematology Chronic Myelogenous Leukemia Working Party. Korean J Med. 88:406–19. DOI:
10.3904/kjm.2015.88.4.406.
Article